Breisgau PHENO-HEART MI: Understanding Heart Attack Biology in Adults
Official title: The Breisgau Pheno Heart Study
Run by University Hospital Freiburg · NCT06166407 · Data updated 2026-11-12
This observational study in adults with STEMI or NSTEMI looks at the body’s immune response after a heart attack to understand how tissue damage and healing affect outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | University Hospital Freiburg Academic / other |
| Locations | 1 site (Freiburg im Breisgau) |
| Status | Recruiting |
| Started | May 15, 2025 |
| Main results expected | April 15, 2028 |
| Study ends | April 15, 2034 |
| Registry record updated | October 27, 2026 |
| Trial ID | NCT06166407 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 presenting with STEMI or NSTEMI undergoing emergency coronary angiography.
✕Probably not a fit
Patients who do not fit the eligibility criteria or who do not experience specific post-infarction inflammatory patterns may not benefit from the study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study observes adults who have had a myocardial infarction to examine how immune cells and inflammation influence heart repair and scar formation after the event. No experimental treatment is given; data are collected from standard care procedures, including emergency coronary angiography. The goal is to identify factors that predict adverse remodeling or complications such as heart failure or arrhythmias. Researchers will analyze biological samples and clinical data to explore how immune responses relate to recovery. Results may inform risk stratification and future therapeutic strategies.
Why it matters
Potential benefit: Findings could help predict which patients are at higher risk for complications after a heart attack and guide future treatments.
How similar studies have gone: Previous observational work has shown that post-infarction inflammation relates to remodeling, but this study explores these associations in a real-world German cohort.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Emergency coronary angiography and age\>18 years and STEMI or NSTEMI or "none of these diseases" Exclusion Criteria: * Hemoglobin\<7,0 g/dl * Platelets \<50.000/µl * Unable to provide written informed consent * Age \> 80 years * hematological neoplasia * metastasized cancers * acute infection (z.B. Sepsis) * Chronic Inflammatory conditions (z.B. inflammatory bowel disease, Rheumatoid arthritis, chronisch hepatitis) * Pregnancy * Immunosuppression * Resuscitation \>5 min oder mehr als 1x Defibrillation vor Koronarangiographie * Cardiogenic shock * Mechanical circulatory support * Cardiomyopathy with an left ventricular ejection fraction F \<40% before the event * Dialysis * Cirrhosis \> CHILD-A * Not living in the county of Breisgau-Hochschwarzwald or Emmendingen oder planned relocation * Alcohol and drug abuse * Non-compliance
Where it's running
-
Department of Cardiology and Angiology, Medical Center - University of Freiburg
Freiburg im Breisgau, Germany Recruiting
Study contacts
- Study coordinator: Patrick M Siegel, MD
- Email: patrick.siegel@uniklinik-freiburg.de
- Phone: +49-761-270-34010
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Registry to optimize management and outcomes for patients with acute myocardial infarction
This study is looking at how well different treatments work for patients who have had a heart attack and received a specific procedure called PCI, to see what helps them recover better.
-
Early single antiplatelet therapy after IVUS-guided PCI in ACS
This study tests whether stopping aspirin early and continuing a potent P2Y12 inhibitor alone is safe and effective after IVUS-guided PCI in people with acute coronary syndrome.
-
Using Dapagliflozin to Prevent Heart Changes After a Heart Attack
This study tests if the medication dapagliflozin can help prevent heart problems in people who have had a heart attack and have some heart weakness.
-
Heart@Home: Safe, at-home care for people with acute heart problems compared with hospital care
This trial tests whether hospital-level care at home can safely and effectively treat adults with acute heart conditions who would normally be in the hospital.
-
Digital cardiac rehab to help heart attack patients improve function
A digital health–supported cardiac rehabilitation program is being tested to see if it helps people after a heart attack improve fitness and stay engaged with rehab, compared with standard outpatient rehab.
-
NMR-based Risk Test and Digital Health Support for midlife adults in Eloisa
This study tests whether an NMR metabolomics risk test can guide tailored digital health programs for midlife adults at risk of diabetes, heart disease, stroke, kidney disease, or fatty liver.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.